Naloxegol for managing opioid-induced constipation.

JAAPA

At the time this article was written, Krystal N. Shelton was a doctor of pharmacy student in the Presbyterian College School of Pharmacy in Clinton, S.C. She is now a pharmacist at CVS Pharmacy. Jennifer N. Clements is an associate professor in the Department of Pharmacy Practice at Presbyterian College School of Pharmacy. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Published: September 2017

Naloxegol is a peripherally acting mu-opioid receptor antagonist for opioid-induced constipation in adults with chronic noncancer pain. This drug's once-daily oral formulation can be used as monotherapy and helps to decrease the constipating effects of opioid therapy; however, it has been associated with abdominal pain.

Download full-text PDF	Source
http://dx.doi.org/10.1097/01.JAA.0000522146.29435.c7	DOI Listing

Publication Analysis

Top Keywords

opioid-induced constipation

naloxegol managing

managing opioid-induced

constipation naloxegol

naloxegol peripherally

peripherally acting

acting mu-opioid

mu-opioid receptor

receptor antagonist

antagonist opioid-induced

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!